The International Society on Thrombosis and Haemostasis issued a clinical practice guideline for the treatment of congenital hemophilia, focusing on hemophilia A and B. The guideline recommends prophylaxis over episodic treatment for severe and moderately severe cases without inhibitors. It also provides guidance on the use of factor concentrates, bypassing agents, nonfactor therapy, and immune tolerance induction. The recommendations are evidence-based and stress the importance of individualized treatment decisions based on patients’ risks, values, and preferences. The guideline emphasizes the complexity of hemophilia management and the need for clarity in treatment decisions. Several authors involved in the guideline have ties to the pharmaceutical industry.
Source link
Organization issues clinical practice guideline for the treatment of hemophilia
